News Teva Pharmaceutical Industries Limited OTC Markets

Equities

TEVJF

IL0006290147

Market Closed - OTC Markets Other stock markets 14:02:46 2024-06-25 EDT			5-day change	1st Jan Change
14.7 ^USD	-18.33%		-18.33%	+70.53%

06-25	Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...
06-25	Teva Pharmaceutical Pays $750 Million to Resolve Tax-Related Litigation	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	06-25
Teva Pharmaceutical Pays $750 Million to Resolve Tax-Related Litigation	06-25	MT
Teva settles tax dispute in Israel with $750 mln payment	06-25	RE
Teva Announces Launch of Authorized Generic of Victoza, in the United States	06-25	AQ
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020	06-25	BU
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020	06-25	CI
Teva Pharmaceutical Launches Generic Victoza in US	06-24	MT
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States	06-24	BU
Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States	06-24	CI
Teva Pharmaceutical Industries 'Well-Positioned' for Further Growth, UBS Says	06-20	MT
Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...	06-14
Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	06-14	MT
Transcript : Teva Pharmaceutical Industries Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM	06-11
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating	06-05	MT
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	06-04	BU
Teva Pharmaceuticals - New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY Extended-Release Injectable Suspension from Invega Sustenna	06-03	AQ
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)	06-01	BU
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024	06-01	BU
Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill	05-30	MT
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)	05-29	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm